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VEGF receptor-2 (VEGFR-2) is expressed on ischemic neurons and astrocytes and is activated by human VEGF
To find out whether VEGFR-2 is expressed and activated in the ischemic brain, we combined immunohistochemical and immunoprecipitation studies. We show that VEGFR-2 is expressed on ischemic neurons and astrocytes at 24 h after reperfusion and that this receptor is phosphorylated (i.e., activated) by VEGF.
VEGF increases phosphorylated Akt and extracellular-regulated kinase (ERK)-1/-2 and reduces phosphorylated p38 and c-Jun NH2-terminal kinase (JNK)-1/-2
To elucidate how VEGF influences cell signaling, we prepared Western blots with tissue samples from ischemic brains. These blots revealed that phosphorylated (but not total, nonphosphorylated) Akt and ERK-1/-2 levels were increased, whereas phosphorylated p38 and JNK-1/-2 levels were reduced by VEGF (Fig. 1) .
VEGF down-regulates inducible NO synthase [inducible NOS (iNOS)] in the ischemic brain
To evaluate whether VEGF influences the expression of iNOS, which contributes to free radical formation in the reperfused brain, we performed immunohistochemistries. Robust expression of iNOS was noticed in ischemic tissue of wild-type (WT) mice (24.7Ϯ6.7 cells/ 62Ј500 m 2 square; mainly NeuNϩ neurons) that was decreased by VEGF (10.3Ϯ4.5 cells/ square, PϽ0.05).
The phosphatidyl inositol-3 kinase (PI3K)/Akt inhibitor Wortmannin reverses VEGF's neuroprotective activity and restores BBB integrity
To clarify the role of the PI3K/Akt pathway in VEGF's effects, we applied the solvent dimethyl sulfoxide (DMSO) or DMSO containing 0.1 mM of the PI3K/Akt inhibitor Wortmannin into the intracerebroventricular (i.c.v.) space of WT and V1tg mice subjected to focal cerebral ischemia, and compared these animals with animals not receiving i.c.v. injections. Whereas cerebral laser Doppler flow (LDF) did not differ between groups ( Fig. 2A) , VEGF reduced infarct volume (Fig. 2B ), improved neurological abnormalities (Fig. 2C) , and increased BBB permeability (Fig. 2E ) without influencing macroscopic brain swelling (Fig. 2D) . Inhibition of PI3K/Akt completely abolished VEGF's neuroprotec-tion (Fig. 2B, C) , at the same time reversing BBB leakage to below levels in wt mice (Fig. 2D, E) .
Reversal of VEGF neuroprotection by Wortmannin is associated with restoration of p38, but not ERK-1/ -2 and JNK-1/-2
To analyze downstream effects of PI3K/Akt, we prepared additional Western blots for DMSO and DMSO/ Wortmannin treated mice. Our data confirmed that Wortmannin indeed inhibited Akt phosphorylation (Fig. 1) . In contrast to phosphorylated ERK-1/-2 and JNK-1/-2, which were not influenced by the PI3K/Akt inhibitor, p38 phosphorylation was increased in Wortmannin treated animals that exhibited exacerbated brain infarcts (Fig. 1) . Our results indicate that the regulation of p38 by VEGF closely depends on the PI3K/Akt activation state.
PI3K/Akt inhibition does not reverse iNOS levels in ischemic neurons
To find out whether iNOS inhibition by VEGF occurs in a PI3K/Akt-dependent manner, we also examined DMSO and DMSO/Wortmannin treated animals by immunohistochemistry. In contrast to MAP kinase/ p38, which was activated when PI3K/Akt was inhibited, neuronal iNOS levels were not reversed by Wortmannin (9.9Ϯ3.0 vs. 8.9Ϯ4.4 cells/square in DMSO and DMSO/Wortmannin-treated mice, respectively), demonstrating that iNOS inhibition by VEGF does not depend on PI3K/Akt.
CONCLUSIONS
Using our transgenic mouse line V1 that expresses human VEGF in the brain, we demonstrate that VEGF protects against focal cerebral ischemia and also induces BBB permeability via the PI3K/Akt pathway. Our data were obtained using: 1) in vivo experiments, in which brain injury was evaluated following 90 min of intraluminal MCA occlusions (24 h reperfusion); 2) immunohistochemical and immunoprecipitation studies using brain tissue samples, in which we examined the expression and phosphorylation (i.e., activation) of VEGF-receptor-2, Akt, MAP kinases (ERK-1/-2, p38, Figure 1 . Expression and phosphorylation state of Akt, ERK-1/-2, MAP kinase/p38, and JNK-1/-2 in WT and V1tg mice subjected to focal cerebral ischemia. Animals were either untreated or i.c.v. treated with 2 l of the solvent DMSO or DMSO containing Wortmannin, a PI3K/Akt inhibitor. Tissue samples were taken from the ischemic cortex and underlying striatum. Note that human VEGF increases phosphorylated (but not total) Akt and ERK-1/-2 and reduces phosphorylated p38 and JNK-1/-2 levels. Furthermore, note the reversal of p38, but not of ERK-1/-2 or JNK-1/-2 phosphorylation in animals treated with Wortmannin, in which Akt phosphorylation was suppressed. Our data suggested that Akt was involved in VEGF's neuroprotective function and BBB permeability. Values are mean Ϯ sd (nϭ3 samples/group), normalized with corresponding blots for ␤-actin. *P Ͻ 0.05 compared with WT mice; # P Ͻ 0.05 compared with V1tg mice receiving DMSO.
JNK-1/-2), and iNOS, as well as 3) additional in vivo experiments, in which we applied the pharmacological PI3K/Akt inhibitor Wortmannin into the i.c.v. space and evaluated effects of VEGF on ischemic injury and BBB permeability. By showing that VEGF: 1) activates VEGFR-2, which as we demonstrate is expressed on ischemic neurons and astrocytes; 2) stimulates Akt and ERK-1/-2; 3) inhibits p38 and JNK-1/-2; and 4) downregulates iNOS, we identify a complex cellular signaling scenario, which VEGF activates in order to exert its neuroprotective function. Based on our finding that the PI3K/Akt pathway is responsible for VEGF's neuroprotection and its BBB permeability, we predict that it may not easily be possible to make use of VEGF's tissue survival without accepting its unfavorable consequence, the increased BBB leakage. VEGF is a homodimeric growth factor that is constitutively expressed in the brain (1, 2) . VEGF is upregulated during hypoxia and ischemia as part of an adaptive response aiming at protecting the tissue from injury (3) (4) . In vitro studies have demonstrated that VEGF protects neurons from death under neurodegenerative conditions (5-7). VEGF's neuroprotective activity was recently shown in vivo after stroke, where VEGF reduced infarct size, ameliorated neurological deficits and prevented delayed neuronal injury by inhibiting caspase-3, when it was supplied locally by intracerebroventricular (i.c.v.) delivery (8) or constitutively expressed in transgenic mice (9) .
In view of its trophic actions on neurons and vascular cells, VEGF is a promising candidate for stroke treatment. Yet, VEGF's survival-promoting effects are purchased at the expense of an increased blood brain barrier (BBB) permeability (10), which potentially compromises tissue survival. Indeed, rodent studies have shown that systemic delivery of VEGF in the early postischemic phase may exacerbate vasogenic edema thus increasing brain damage, while VEGF antagonisation with the high-affinity VEGF-binding protein mFlt(1-3)-IgG reduced brain swelling and infarct size (11, 12) . In face of the detrimental consequences of malignant edema, making use of VEGF's protective effects but avoiding its vascular permeability would be desirable, when VEGF is therapeutically used.
The mechanisms via which VEGF protects the brain against ischemia and induces BBB permeability remained largely unknown. To elucidate effects of VEGF in the brain, we have recently established transgenic mice expressing human VEGF 165 in the central nervous system (CNS) under control of a neuron-specific enolase (NSE) promoter (so-called V1tg mouse line; 13). When submitted to intraluminal middle cerebral artery (MCA) occlusion, V1tg animals exhibited smaller brain infarcts than wild-type (WT) mice, despite an increased vascular permeability (9) . To characterize the signaling mechanisms responsible for VEGF's neuroprotective properties, we now studied the expression and phosphorylation (i.e., activation) of VEGF receptor-2 (VEGFR-2, Flk-1), the phosphatidylinositol-3 kinase (PI3K)-dependent factor Akt and of mitogen activated protein (MAP) kinases (extracellular-regulated kinase (ERK)-1/-2, p38 and Jun kinase (JNK)-1/-2) and analyzed inducible NO synthase (iNOS) expression in WT and V1tg mice submitted to focal cerebral ischemia. We then modulated the activity of one of the signal transduction factors, Akt, by delivering a pharmacological inhibitor, Wortmannin, investigating the role of the PI3K/ Akt pathway in VEGF's neuroprotective function and BBB permeability.
MATERIALS AND METHODS

Animals
All animal experiments were carried out with governmental approval according to National Institutes of Health guidelines for care and use of laboratory animals. The generation and characterization of the NSE-VEGF transgenic mouse line V1, which were backcrossed on a C57Bl/6 background, have been previously described in detail (9) .
Induction of intraluminal MCA occlusions
Adult V1tg mice and their nontransgenic littermates (21-28 g) were anesthetized with 1% halothane (30% O 2 , remainder N 2 O) (nϭ11 animals/ group). Rectal temperature was maintained between 36.5 and 37.0°C by using a feedback-controlled heating system. Focal ischemia was induced using an intraluminal technique (9, 14) using a 8 -0 silicon coated (Xantopren: Bayer Dental, Osaka, Japan) nylon monofilament (Ethilon; Ethicon, Norderstedt, Germany). During the experiments, laser Doppler flow (LDF) was monitored using a flexible 0.5 mm fiberoptic probe (Perimed, Stockholm, Sweden) attached to the intact skull overlying the MCA territory. LDF changes were measured during 90 min of MCA occlusion and up to 30 min after reperfusion onset. At that time, wounds were carefully sutured and anesthesia was discontinued. After 24 h of reperfusion, neurological deficits were evaluated using a five-point neurological deficit score ranging from 0 ϭ normal function to 4 ϭ absence of spontaneous motor activity (15, 9) . Animals were then reanesthetized with halothane and sacrificed. Brains were removed, frozen on dry ice, and cut on a cryostat into coronal 18 m sections that were used for cresyl violet stainings and for immunohistochemistry for extravasated IgG, VEGFR-2, and iNOS. In addition, tissue samples were taken from the ischemic brain (striatum and overlying cortex) at the level of the bregma for immunoprecipitation studies and Western blots. Histological injury was evaluated on cresyl violet sections taken from five equidistant brain levels, 2 mm apart, on which infarct borders between infarcted and noninfarcted tissue were outlined using an image analysis system (Image J). Thus, infarct volume and brain swelling were determined.
Analysis of serum IgG extravasation
With gentle stirring, brain sections were rinsed for 10 min at room temperature in 0.1 M phosphate buffered saline (PBS), in order to remove intravascular IgG, and were fixed in 4% paraformaldehyde (16) . Following blocking of endogenous peroxidase with methanol/ 0.3% H 2 O 2 and immersion in 0.1 M PBS containing 5% bovine serum albumin (BSA) and normal swine serum (1:1000), sections were incubated for 1 h in biotinylated anti-mouse IgG (Santa Cruz, Nunningen, Switzerland) and stained with an avidin peroxidase kit (Vectastain Elite; Vector Labs, Burlingame, CA) and diaminobenzidine (Sigma, Deisenhofen, Germany). For reasons of data comparability, all sections were processed in parallel. Sections were scanned and densitometrically analyzed (nϭ5-6 animals/group). IgG extravasation was analyzed by subtracting optical densities in the contralateral nonischemic from that in the ischemic cortex and underlying striatum.
Immunohistochemistry of VEGFR-2 and inducible NO synthase (iNOS)
Brain sections were fixed in ice-cold acetone (VEGFR-2) or 4% paraformaldehyde/0.1 M PBS (iNOS), washed, and immersed for 1 h in 0.1 M PBS containing 0.3% Triton X-100 (PBS-T)/10% normal goat serum. Sections were incubated overnight at 4°C with monoclonal rat antimouse VEGFR-2 (Flk-1; 9) or polyclonal rabbit anti-inducible NOS (NOS-2, sc-650; Santa Cruz) antibody (Ab), diluted 1:100 in PBS-T. Counterstainings were performed with a mouse Ab against the neuronal nuclear protein NeuN (MAB377, Chemicon, Lucerne, Switzerland; 1:500) or with a goat Ab against the astrocytic marker glial acidic fibrillary protein (GFAP) (Molecular Probes, Basle, Switzerland; 1:250). Sections were finally incubated with 4Ј,6Ј-diamidino-2-phenylidole (DAPI) and cover-slipped.
Sections stained for VEGFR-2 were evaluated by counting the density of VEGFR-2(ϩ) parenchymal (i.e., nonvascular) cells in rectangular fields of the cerebral (sensory) cortex close to the infarct border and in the nonischemic (cingulate) cortex located outside the MCA territory (area evaluated: 62Ј500 m 2 ). These VEGFR-2(ϩ)cells could clearly be distinguished based on their size, which was bigger than that of newborn capillary endothelial cells, which are also VEGFR-2(ϩ). Sections stained for iNOS were analyzed by counting iNOS(ϩ) cells in a total of four regions within the parietal cortex (62Ј500 m 2 ), for which mean values were calculated. The regions chosen for this assessment were located within the evolving infarct, thus ruling out that differences in cell densities were a consequence of the severity of brain injury that differed between groups.
centrifuged at 14,000 rpm for 20 min at ϩ 4°C, washed four times with lysis buffer and resuspended in sodium dodecylsulphate (SDS) sample buffer, boiled for 5 min, and analyzed by Western blotting. Protein concentration was determined using a Bio-Rad protein assay kit. 20 g of immunoprecipitated proteins were electrophoresed on 7% SDS-PAGE and transferred onto PVDF membranes. Membranes were then blocked with 5% nonfat milk solution in 10 mM Tris-HCl, pH 7.4/150 mM NaCl and 0.5% Nonidet p-40 at room temperature for 1 h and incubated with mouse monoclonal antip-Tyr Ab (PY99; sc-7020; Santa Cruz Biotechnology), diluted 1:500. Membranes were stripped and reprobed with VEGFR-2 Ab (200 g/ml) to ascertain equal loading of protein. The phosphorylation state of VEGFR-2 was analyzed densitometrically on the p-Tyr blots and normalized with the concentration of total VEGFR-2 expression.
Western blots
Tissue samples harvested from the striatum and overlying cortex of ischemic WT and V1tg mice were complemented with lysis buffer, homogenized, and centrifuged. Supernatants were used for SDS-PAGE. Prior to processing, samples from animals belonging to the same experimental group (nϭ5-6 animals/group) were pooled. After SDS-PAGE, proteins were transferred onto PVDF membranes. Membranes were dried, incubated in blocking solution and immersed with polyclonal rabbit antitotal (detecting both the phosphor- 
Inhibition of the PI3K/ Akt pathway
By means of a glass microelectrode with a tip outer diameter of 50 m, 2 l of either: 1) 100% dimethyl sulfoxide (DMSO) or 2) the PI3K/Akt inhibitor Wortmannin (0.1 mM; Sigma), dissolved in 100% DMSO, was carefully injected i.c.v. in WT and V1tg mice (nϭ5-6 animals/group). After 30 min, animals were submitted to MCA occlusions, according to the same procedure as described above. After 24 h, neurological deficits were evaluated. Then, animals were deeply re-anesthetized and sacrificed. Brains were cut in 18 m cryostate sections, and tissue samples were also harvested from the MCA territory.
Statistics
Measurements were performed by two investigators blinded for the experimental conditions. For statistical analysis, a standard software package [Statistical Packages for the Social Sciences (SPSS) for Windows 10.1] was used. Values are given as means Ϯ sd. Differences between groups were compared by using one-way ANOVA, followed by least significant differences tests. P-values less than 0.05 were considered significant.
RESULTS
VEGF receptor-2 (VEGFR-2) is expressed on ischemic neurons and astrocytes and is activated by human VEGF
VEGFR-2 has been made responsible for VEGF's neuroprotective function in vitro (5) . To find out whether VEGFR-2 is expressed in the V1tg mouse brain, which is protected against focal cerebral ischemia and also reveals an increased BBB permeability after stroke (9), we examined VEGFR-2 expression by immunohistochemistry. In the nonischemic cerebral cortex, VEGFR-2 was detected mainly on brain capillaries (9) . In the ischemic cortex, however, a distinct signal of VEGFR-2 was also noted on NeuNϩ neurons and GFAPϩ astrocytes of WT and V1tg animals, particularly in the infarct borderzone (Fig. 1A, B) .
To test, whether human VEGF activates the VEGFR-2, we precipitated this receptor from tissue samples obtained from the ischemic MCA territory that we further analyzed with a phospho-tyrosine Ab. Our experiments revealed an increased phosphorylation state of VEGFR-2 in V1tg mice (Fig. 2) , confirming that VEGFR-2 was functional.
VEGF increases phosphorylated Akt and ERK-1/-2 and reduces phosphorylated p38 and JNK-1/-2 levels
To elucidate how VEGF influences cytosolic cell signaling, we prepared Western blots with ischemic tissue samples. Total levels of Akt, but not ERK-1/-2, p38, and JNK-1/-2, were lower in ischemic V1tg than WT mice (Fig. 3) , which, however, did not reflect the levels of the phosphorylated proteins. As such, phosphorylated Akt and ERK-1/-2 levels were increased, whereas phosphorylated p38 and JNK-1/-2 levels were reduced in V1tg brains (Fig. 3) . Our data suggested an involvement of the PI3K/Akt pathway in VEGF's effects on ischemic injury and BBB integrity.
VEGF down-regulates inducible NO synthase (iNOS) in ischemic neurons
To evaluate whether VEGF influences the expression of iNOS, which contributes to free radical formation in the reperfused brain and presumably exacerbates ischemic damage (18), we performed immunohistochemical stainings for iNOS. Robust expression of iNOS was noticed in ischemic brain regions of WT mice that was significantly diminished by human VEGF (Fig. 4A, B) . Double-stainings for NeuN revealed that a large percentage of iNOSϩ cells (Ͼ50%) were neurons (Fig.  4A ). Our observations propose that neuroprotection by VEGF involves the down-regulation of iNOS.
The PI3K/Akt inhibitor Wortmannin reverses VEGF's neuroprotective properties and restores BBB integrity
To clarify the role of the PI3K/Akt pathway in VEGF's effects on neuronal survival and BBB permeability, we examined the influence of 2 l of the solvant DMSO or of DMSO containing 0.1 mM Wortmannin in WT and V1tg mice submitted to focal cerebral ischemia. LDF measurements during ischemia did not reveal any differences between groups, neither when WT and V1tg animals were studied, nor when DMSO or DMSO/ Wortmannin were compared (Fig. 5A ). Yet, PI3K/Akt inhibition with Wortmannin completely abolished VEGF's neuroprotection, both infarct volume (Fig. 5B ) and neurological deficits (Fig. 5C ) being reversed to levels in WT mice. At the same time, brain swelling ( Fig.  5D ) and IgG extravasation (Fig. 5E) were attenuated by the PI3K/Akt blockade. Thus, brain edema and BBB permeability dropped below levels in WT animals (Fig.  5D, E) . In WT mice, the delivery of Wortmannin did not have any effect (Fig. 5A-E) . Our results confirm that the PI3K/Akt pathway is indeed responsible for both, VEGF's neuroprotection and BBB leakage.
Reversal of VEGF neuroprotection by Wortmannin associated with restoration of p38, but not ERK-1/-2 and JNK-1/-2
To analyze downstream effects of PI3K/Akt in VEGFneuroprotection mice, we also prepared Western blots with tissue samples obtained from DMSO and DMSO/ Wortmannin treated mice. In these blots, we confirmed that Wortmannin indeed inhibits Akt phosphorylation (Fig. 3) . In contrast to phosphorylated ERK-1/-2 and JNK-1/-2, which were not influenced by the PI3K/Akt inhibitor, p38 phosphorylation was increased in Wortmannin-treated animals that exhibited exacerbated Figure 1 . VEGF receptor-2 (VEGFR-2) is expressed on ischemic neurons and astrocytes after focal cerebral ischemia. Immunohistochemistries revealing VEGFR-2ϩ/NeuNϩ neurons and VEGFR-2ϩ/GFAPϩ astrocytes in the ischemic (sensory) cortex close to the infarct border of WT mice (A). Note that VEGFR-2 expression does not differ between WT and V1tg mice (B). VEGFR-2 was rarely expressed on parenchymal cells in the nonischemic brain. Graphs show parenchymal cells (i.e., neurons and astrocytes), evaluated in squares measuring 62Ј500 m 2 , expressed as means Ϯ sd (nϭ7-8 animals/ group).
* P Ͻ 0.05 compared with nonischemic mice. Fluorescent dyes: VEGFR-2, Cy-3 (red); NeuN, FITC (green); GFAP, FITC (green); DAPI (blue). Bar, 60 m. brain infarcts (Fig. 3) , suggesting that p38 phosphorylation closely depends on the PI3K/Akt activation state.
PI3K/Akt inhibition does not restore iNOS levels
In order to find out whether iNOS inhibition by VEGF occurs in a PI3K/Akt-dependent manner, we further analyzed brain sections from DMSO and DMSO/Wortmannin-treated mice that we stained for iNOS. In contrast to MAP kinase/p38, which was activated when PI3K/ Akt was blocked, iNOS levels were not reversed by Wortmannin (Fig. 4) , demonstrating that iNOS inhibition by VEGF does not depend on PI3K/Akt.
DISCUSSION
We demonstrate that the PI3K/Akt pathway mediates VEGF's neuroprotective activity and also induces BBB permeability after focal cerebral ischemia. Our data were obtained using the transgenic mouse line V1 that expresses human VEGF under a NSE promoter (13) . We submitted these mice to 90 min of intraluminal MCA occlusion and examined cell signaling factors involved in VEGF's neuroprotective function and BBB integrity, by combining IgG extravasation studies with histochemical (Western blotting, immunocytochemistry, immunoprecipitation) and pharmacological (i.c.v. delivery of PI3K/ Akt inhibitor Wortmannin) experiments. We have previously shown in V1tg mice that human VEGF protects against ischemia in a caspase-3 dependent manner and ameliorates neurological deficits after stroke, despite an increased vascular permeability that was noticed in V1tg mice (9) . The survival-promoting effects of VEGF were not due to hemodynamic improvements. Conversely, a reduction of cerebral blood flow was noticed in ischemic regions of V1tg mice by 14 C-iodoantipyrine autoradiography, which could be attributed to a hemodynamic steal of blood from ischemic to nonischemic regions (9) .
VEGFR-2 is expressed on ischemic neurons and astrocytes and is activated by human VEGF
If VEGF indeed has neuroprotective effects in the brain, as our earlier data indicated (9), the question arises of how VEGF exerts its neuroprotective function. By demonstrating that VEGFR-2 is expressed on ischemic neurons and astrocytes, VEGFR-2 being activated by human VEGF, we provide in vivo evidence that VEGF may directly promote neuronal survival. In vivo, VEGFR-2 has previously been shown on endothelial cells under physiological conditions, but not on neurons and glial cells (19) . From in vitro studies it was already known that neurons can express VEGFR-2 (5) (6) (7) , in addition to VEGF receptor-1 (6, 7) and neuropilin-1 (5), another VEGF receptor. As VEGFR-2 but not VEGF receptor-1 antisense oligonucleotides reversed VEGF's neuroprotective activity (6) and neuropilin-1 ligands were unable to mimic VEGF's survival effects (5), it was concluded that VEGFR-2 was responsible for VEGF's neuroprotection. Based on our present results, VEGFR-2 is expressed and activated on neurons and astrocytes in vivo following stroke, but not under physiological conditions.
Role of the PI3K/Akt pathway in VEGF's neuroprotective activity
In accordance with in vitro findings indicating that VEGF induces neuroprotection via the PI3K/Akt and ERK-1/-2 pathways downstream of VEGFR-2 (5) (6) (7) 20) and in agreement with very recent data showing elevated phosphorylated Akt levels in the ischemic brain (21), we demonstrate that VEGF stimulates Akt and ERK-1/-2 phosphorylation in the stroke brain. Although the brain comprises various cell-types, which may respond differently to ischemia and other types of injury, Western blotting is a very useful tool that allows us to evaluate molecular actions of brain-protective molecules. Indeed, in pharmacological experiments using the PI3K/Akt inhibitor Wortmannin, we show that the PI3K/Akt pathway mediates VEGF's survivalpromoting function. Our observation that VEGF induces neuroprotection via the PI3K/Akt pathway is noteworthy, as this pathway stabilizes mitochondrial function under conditions in which tissue oxygen levels are compromised. Via phosphorylation of Bad, activated Akt releases Bcl-X L inside the mitochondria, which in turn prevents formation of the mitochondrial permeability transition pore and preserves the mitochondrial membrane potential (e.g., see 15). Bcl-X L , on the other hand, once released from Bad, blocks the secretion of cytochrome c from injured mitochondria, thereby inhibiting caspase-9 and -3 and preventing DNA cleavage (15) .
Role of PI3K/ Akt in VEGF-induced BBB permeability
That the PI3K/Akt pathway also mediates VEGF's BBB permeability, besides its neuroprotective influence, is a further major result of our study. Despite in vitro reports, which already suggested previously that the PI3K/Akt pathway is involved in VEGF's endothelial permeability (22) , it has to our knowledge not been demonstrated that PI3K/Akt signaling mediates vascular permeability after stroke. This finding is of interest, as vascular permeability and infarct size were inversely related to each other. In endothelial culture, it was previously shown that VEGF's vascular permeability is mediated via serine/threonine phosphorylation and redistribution of tight junction proteins, zona occludens-1, and occludin, which are controlled by PI3K/Akt (22, 23) . It is noteworthy that Wortmannin did not influence brain swelling and BBB integrity in WT mice. This points toward a specific role of the PI3K/Akt pathway in VEGF's BBB permeability.
Inhibition of MAP kinase/p38 but not JNK-1/-2 by VEGF depends on PI3K/ Akt activity
Elevated levels of VEGF in our transgenic mice not only stimulated Akt and ERK-1/-2 but also inhibited MAP kinase/ p38 and JNK-1/-2. p38 and JNK-1/-2 are both stress-inducible kinases, which are strongly activated in injured neurons (for review, 25). We previously found that acute hypoxia-induced VEGF expression in the brain resulted in p38-mediated edema formation (24) . It is known that acute increases in VEGF levels lead to edema formation, while delayed VEGF elevations do not (12) . The difference may result from an attenuated p38 response when sustained elevated VEGF levels are present. Indeed, no signs of edema formation were found in the brain of V1tg mice, despite the presence of high VEGF levels. Interestingly, the inhibition of p38 but not of JNK-1/-2 in VEGF overexpressing mice was reversed by Wortmannin. This suggests that the regulation of MAP kinase/p38 by VEGF closely depends on PI3K/Akt.
Inhibition of iNOS by VEGF does not depend on the PI3K/ Akt pathway
The inhibition of iNOS levels by VEGF, which we found predominantly in neurons, is also new and may represent a hitherto unknown player also in the context of VEGF's neuroprotection. Indeed, iNOS is supposed to exacerbate ischemic damage after stroke, as it contributes to free radical stress via formation of nitrite and nitrate (18) . Based on our data, VEGF may protect the brain tissue by reducing tissue levels of these highly toxic compounds. Inhibition of iNOS after focal cerebral ischemia has recently been shown by us also for another hypoxia-inducible factor, erythropoietin, which is also protective after brain ischemia (14) . It is noteworthy that both in our recent study (14) and the present experiments, iNOS inhibition was not reversed by Wortmannin, which indicates that iNOS inhibition occurs PI3K/Akt independently. Our data show that VEGF and erythropoietin share common signaling mechanisms that provide protection against free radical damage in the hypoxic-ischemic brain.
CONCLUSIONS
By demonstrating that human VEGF activates VEGFR-2, Akt, and ERK-1/-2 and inhibits MAP kinase/p38, JNK-1/-2 and iNOS in the ischemic brain, we provide insight into the signaling pathways underlying VEGF's neuroprotective activity. We show that the PI3K/Akt pathway mediates VEGF's neuroprotection and BBB permeability in mice submitted to focal cerebral ischemia, most likely in a VEGFR-2 dependent way. Based on our finding that the same PI3K/Akt pathway is responsible for VEGF's survival promoting function and BBB leakage, we predict that it may not easily be possible to make use of VEGF's neuroprotective action after stroke without accepting its unfavorable consequence, the increased BBB permeability.
